However, differences in HER2 expression before and after trastuzumab were reported in HER2-positive gastric cancer and it is related with efficacy of trastuzumab in cross-line therapy [2, 3].Therefore, it is imperative to update HER2 status just before treatment. The gene discussed is ERBB2; the disease is gastric cancer.